To The Moon

Moderna Financial Analysis

Key Takeaways

Moderna (MRNA, Financial) is the most shorted stock in the S&P 500 as of September, with 18.66% of shares sold short. Despite high short interest, Moderna's stock price increased by 6.7% over the past month.

Company Overview Moderna (MRNA) emerged as the most shorted stock in the S&P 500 during September, with 18.66% of its shares sold short, an increase from 17.42% in August. Despite this, the company's stock price rose by 6.7% over the past month, outperforming both the broader medical sector's 1.17% gain and the S&P 500's 4.2% rise.

Founded in 2010, Moderna is a commercial-stage biotechnology company that gained significant attention with its mRNA technology, particularly through its COVID-19 vaccine authorized in December 2020. The company is actively involved in developing 35 mRNA candidates across various therapeutic areas, including infectious diseases, oncology, cardiovascular, and rare genetic diseases.

With a market capitalization of $10.4 billion, Moderna operates within the healthcare sector, specifically in the biotechnology industry. The company is listed on the NASDAQ exchange.

Financial Health Analysis

Moderna's financial performance presents a mixed picture:

Revenue: $3.055 billion, with a 3-year growth rate of -41.3%. Gross Margin: 52.14%, indicating a moderate level of profitability. Net Margin: -95.03%, reflecting significant challenges in achieving profitability. Debt-to-Equity Ratio: 0.08, suggesting a strong balance sheet with low leverage. Current Ratio: 3.93, indicating robust liquidity. Warning signs include a declining revenue per share over the past three years.

Valuation & Market Sentiment

Moderna's valuation metrics provide insight into its market positioning:

Price-to-Sales Ratio: 3.44, compared to a historical median of 6.57. Price-to-Book Ratio: 1.11, below the historical median of 3.8. Analyst target price: $46.5, with a recommendation score of 3.1. Technical indicators: RSI (14) at 51.59, suggesting a neutral market sentiment. Institutional ownership stands at 75.08%, with insider ownership at 5.87%.

Risk Assessment

Moderna's risk profile is shaped by several factors:

Financial health grades indicate a GF Score of 61, suggesting modest overvaluation. Sector-specific risks include the competitive and regulatory landscape of the biotechnology industry. Volatility is high, with a beta of 1.31, indicating greater sensitivity to market movements.

$Moderna, Inc.(MRNA)$ $CRISPR Therapeutics AG(CRSP)$ $CureVac B.V.(CVAC)$ $Robinhood(HOOD)$ $Novavax(NVAX)$